A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects

• ClinicalTrials.gov Identifier: NCT02788721
• Recruitment Status: Completed
• First Posted: June 2, 2016
• Last Update Posted: July 12, 2017
• Sponsor: Galapagos NV
• Collaborators: Pharmaceutical Research Associates; SGS S.A.
• Information provided by (Responsible Party): Galapagos NV

Study Description

Brief Summary:

The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled study evaluating single and multiple ascending oral doses of GLPG2451 and combined multiple doses of GLPG2451 and GLPG2222 in healthy female subjects. The purpose of the study is to evaluate safety and tolerability after single ascending oral doses and of multiple doses of GLPG2451 given to healthy female subjects compared to placebo as well as of multiple doses of the combination of GLPG2451/GLPG2222 compared to GLPG2451/placebo.

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: GLPG2451 single dose; Drug: Placebo	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 31 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Basic Science
• Official Title: Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG2451 and of the Combination of GLPG2451 and GLPG2222 in Healthy Female Subjects
• Actual Study Start Date: April 14, 2016
• Actual Primary Completion Date: April 27, 2017
• Actual Study Completion Date: April 27, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: GLPG2451 single dose; Single dose of GLPG2451 oral suspension at up to 4 dose levels in ascending order	Drug: GLPG2451 single dose; GLPG2451 oral suspension, single ascending doses, daily
Placebo Comparator: Placebo single dose; Single dose of Placebo oral suspension	Drug: Placebo; Placebo, oral suspension, daily

Outcome Measures

Primary Outcome Measures :

1. Change versus placebo in the proportion of subjects with adverse events [ Time Frame: Between screening and 182 days after the last dose ]
   To assess safety and tolerability of single ascending doses with GLPG2451 versus placebo in healthy subjects

Secondary Outcome Measures :

1. Maximum observed plasma concentration of GLPG2451 (Cmax) given alone [ Time Frame: Between day 1 predose and 175 days after the last dose ]
   To characterize pharmacokinetics of GLPG2451 and its metabolite after a single oral dose in healthy subjects
2. Time of occurrence of Cmax for GLPG2451 and (tmax) given alone [ Time Frame: Between day 1 predose and 175 days after the last dose ]
   To characterize pharmacokinetics of GLPG2451 and its metabolite after a single oral dose in healthy subjects
3. Area under the plasma concentration-time curve (AUC0-t) of GLPG2451 given alone [ Time Frame: Between day 1 predose and 175 days after the last dose ]
   To characterize pharmacokinetics of GLPG2451 and its metabolite after a single oral dose in healthy subjects

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Female between 18-65 years of age inclusive, on the day of signing informed consent form (ICF).
• Of non-childbearing potential defined as surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy), or post-menopausal (at least 12 consecutive months without menstruation, without an alternative medical cause [including hormone replacement therapy]). In addition a determination of follicle stimulating hormone (FSH) can be performed with FSH >35 mIU/ml to further confirm postmenopausal status without menstruation for ≥12 months.
• A body mass index (BMI) between 18-30 kg/m2, inclusive.
• Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), Holter monitoring and a laboratory profile prior to the initial study drug administration.
• Discontinuation of all medications (including over-the-counter medications and herbal supplements) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks prior to the first study drug administration. In addition, subjects must agree not to take any medications (including over-the-counter medication and herbal supplements), or alcohol during the course of the study.-non-smokers and non-users of any nicotine-containing products.
• Non-smokers and non-users of any nicotine-containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to the screening. A non-user is defined as an individual who has abstained from any nicotine containing products for at least 1 year prior to the screening.
• Negative urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, and tricyclic antidepressants) and alcohol breath test.
• Able and willing to sign the ICF as approved by the IEC, prior to screening evaluations, and willing to adhere to the prohibitions and restrictions.

Exclusion Criteria:

• Known hypersensitivity or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
• Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or any history of hepatitis from any cause with the exception of hepatitis A.
• History of or a current immunosuppressive condition (e.g., human immunodeficiency virus [HIV] infection).
• Symptoms of clinically significant illness in the 3 months before the initial study drug administration.
• Presence or having sequelae of gastrointestinal, liver or kidney (creatinine clearance ≤ 80 mL/min using the Cockroft formula; if calculated result ≤ 80 mL/min, a 24-hour urine collection to determine actual value can be done) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
• History of malignancy within the past 5 years (except for basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been treated with no evidence of recurrence).
• Clinically relevant abnormalities detected on ECG and/or Holter regarding either rhythm or conduction (e.g. QTcF ≥ 470 msec, or a known long QT syndrome). A first degree heart block will not be considered as a significant abnormality.
• Family history (if known) of long QT syndrome in a primary relative.
• Clinically relevant abnormalities detected on vital signs.
• Significant blood loss (including blood donation [> 500 mL]), or having had a transfusion of any blood product within 12 weeks prior to the initial study drug administration.

Contacts and Locations

Locations

Belgium

SGS LSS Clinical Pharmacology Unit Antwerp

Antwerp, Belgium

Sponsors and Collaborators

Galapagos NV

Pharmaceutical Research Associates

SGS S.A.

Investigators

• Study Director: Chris Brearley, MD; Galapagos NV

More Information

• Responsible Party: Galapagos NV
• ClinicalTrials.gov Identifier: NCT02788721
• Other Study ID Numbers: GLPG2451-CL-101
• First Posted: June 2, 2016
• Last Update Posted: July 12, 2017
• Last Verified: July 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided